Enliven Therapeutics

(NASDAQ) ELVN

Current Price$45.10

Market Cap$3.22B

Since IPO (2023)+89%

5 Year+50%

1 Year+109%

1 Month+12%

Enliven Therapeutics Financials at a Glance

Market Cap

$3.22B

Revenue (TTM)

$0.00

Net Income (TTM)

-$98.78M

EPS (TTM)

-$1.66

P/E Ratio

-27.11

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$45.10

Volume

2,449,816.884

Open

$45.00

Price

$45.10

Volume

2,449,816.884

Open

$45.00

Previous Close

$45.10

Daily Range

$44.22 - $45.72

52-Week Range

$14.79 - $48.53

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$45.10

Volume

2,449,816.884

Open

$45.00

Previous Close

$45.10

Daily Range

$44.22 - $45.72

52-Week Range

$14.79 - $48.53

Estimated Earnings Date

Aug 12, 2026

ELVN News

Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.

Robert IzquierdoJun 1, 2026

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Jonathan PoncianoMay 13, 2026

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Cory RenauerMar 28, 2026

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k

Adé HennisFeb 1, 2026

Enliven Posts Loss Beat and Cash Surge

Motley Fool Markets TeamAug 13, 2025

ELVN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Enliven Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Richard A. Fair, MBA

Website

www.enliventherapeutics.com

Headquarters

Boulder, CO 80301, US

ELVN Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-27%

Return on Capital

-26%

Return on Assets

-21%

Earnings Yield

-3.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.22B

Shares Outstanding

71.44M

Volume

2.45M

Avg. Volume

1.38M

Financials (TTM)

Gross Profit

-$263.00K

Operating Income

-$119.66M

EBITDA

-$103.43M

Operating Cash Flow

-$70.30M

Capital Expenditure

-$158.00K

Free Cash Flow

-$70.46M

Cash & ST Invst.

$462.62M

Total Debt

$399.00K

Enliven Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$14.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.22B

N/A

Market Cap/Employee

$51.97M

N/A

Employees

N/A

Net Income

-$23.63M

+17.2%

EBITDA

-$23.61M

+17.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$452.40M

+56.2%

Total Debt

$302.00K

-17.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$302.00K

-17.3%

Return on Assets

-21.25%

N/A

Return on Invested Capital

-25.54%

N/A

Free Cash Flow

-$19.29M

+20.1%

Operating Cash Flow

-$19.29M

+20.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

DNTHDianthus Therapeutics, Inc.

DNTHDianthus Therapeutics, Inc.$82.49+0.73%

RLAYRelay Therapeutics, Inc.

RLAYRelay Therapeutics, Inc.$15.88+2.06%

SNDXSyndax Pharmaceuticals, Inc.

SNDXSyndax Pharmaceuticals, Inc.$19.00-0.21%

ATAIAtai Beckley Inc.

ATAIAtai Beckley Inc.$4.06-0.25%

PGENPrecigen, Inc.

PGENPrecigen, Inc.$4.82+1.90%

INBXInhibrx Biosciences, Inc.

INBXInhibrx Biosciences, Inc.$93.05-1.22%

IMTXImmatics N.V.

IMTXImmatics N.V.$9.78+2.73%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$13.49-0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.99+0.04%

TAT&T

TAT&T$22.01-0.02%

AAPLApple

AAPLApple$298.01+0.01%

CMCSAComcast

CMCSAComcast$22.43-0.01%

BACBank of America

BACBank of America$56.20-0.01%

RKLBRocket Lab

RKLBRocket Lab$107.24-0.01%

Questions About ELVN

What is the current price of Enliven Therapeutics?

Enliven Therapeutics is trading at $45.10 per share.

What is the 52-week range for Enliven Therapeutics?

Over the past 52 weeks, Enliven Therapeutics has traded between $14.79 and $48.53.

How much debt does Enliven Therapeutics have?

As of the most recent reporting period, Enliven Therapeutics reported total debt of $302.00K.

How much cash does Enliven Therapeutics have on hand?

Enliven Therapeutics reported $132.18M in cash and cash equivalents in its most recent financial results.

What is Enliven Therapeutics’s dividend yield?

Enliven Therapeutics does not currently have a dividend yield.

Enliven Therapeutics

Enliven Therapeutics Financials at a Glance

ELVN News

Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k

Enliven Posts Loss Beat and Cash Surge

ELVN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Enliven Therapeutics

ELVN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Enliven Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ELVN

What is the current price of Enliven Therapeutics?

What is the 52-week range for Enliven Therapeutics?

How much debt does Enliven Therapeutics have?

How much cash does Enliven Therapeutics have on hand?

What is Enliven Therapeutics’s dividend yield?

Premium Investing Services